Last updated: 2026-09-09 11:52:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Marker Therapeutics, Inc. (MRKR) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.26, with a market capitalization of $19.67M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.83 to $2.46. This page covers its latest market performance, valuation, price trends and company information.
$19.67M | |
$1.19 | |
$102.50 | |
$0.67 | |
$1.18 | |
193.75K | |
66.86K | |
-- | |
$2.46 | |
$0.83 | |
-- | |
-- |
Marker Therapeutics, Inc. (MRKR) is trading at $1.30 in pre-market trading as of 2026-09-08 23:31:00, up 10.17% ($0.12) from the previous close of $1.18
Pre-market trading shows how investors are pricing MRKR before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Marker Therapeutics, Inc. (MRKR) moved from $1.37 to $1.26, representing a decline of 8.10% ($0.11).
The stock traded between $1.12 and $1.50 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 87.48 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 26.3%
MRKR is currently trading at $1.26, placing it 26.3% of the way from its 52-week low of $0.83 to its 52-week high of $2.46. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 5 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Marker Therapeutics, Inc. (MRKR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.